Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jan 25;18:16. doi: 10.1186/s12890-017-0571-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 3 — Respiratory-related medication use in the 12 months following the index date^a. ^aOnly medications prescribed to >1% of patients in at least two cohorts are presented. ^bAll comparisons with ACO were statistically significant (p ≤ 0.001) except for the use of oral systemic corticosteroids (≤14 days) between the ACO and COPD cohorts (p = 0.500). ACO, asthma-COPD overlap; COPD, chronic obstructive pulmonary disease; CS, corticosteroid; ICS, inhaled corticosteroid; IgE, immunoglobulin E; LABA, long-acting β₂-agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist; NS, not significant; SABA, short-acting β₂-agonist; SABD, short-acting bronchodilator; SAMA, short-acting muscarinic antagonist; Sys, systemic